Entering text into the input field will update the search result below

Threshold Pharma cancer drug candidate Fast Track'd

Nov. 11, 2014 12:30 PM ETMolecular Templates, Inc. (MTEM) StockBy: Douglas W. House, SA News Editor1 Comment
  • The FDA grants Fast Track status to Threshold Pharmaceuticals' (THLD +9.1%) TH-302 for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma. The product candidate is in Phase 3 development for this indication. The primary analysis of overall survival will be done in Q1 2016.
  • Fast Track status allows for more frequent interactions with the FDA and a rolling review of the NDA in order to expedite the approval process.

Recommended For You

About MTEM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MTEM--
Molecular Templates, Inc.